Study detail
RecruitingPhase 1
An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
Biohaven Therapeutics Ltd.
Summary
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Detailed criteria
Key Inclusion Criteria: 1\. Participants must have serologically confirmed Graves' Disease. Key Exclusion Criteria: 1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit. 2. History of treatment with radioactive iodine or thyroid surgery.